Last reviewed · How we verify
NCT01616303
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Phase 2 trial testing Carboplatin in Ovarian Neoplasms in 97 participants. Completed in 12 October 2018.
15 June 2015
Quick facts
| Lead sponsor | Quest PharmaTech Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 97 |
| Start date | 15 June 2012 |
| Primary completion | 15 June 2015 |
| Estimated completion | 12 October 2018 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Carboplatin (Carboplatin) — full drug profile →
- Paclitaxel — full drug profile →
- oregovomab — full drug profile →
Conditions studied
- Ovarian Neoplasms — all drugs for Ovarian Neoplasms →
Sponsor
Quest PharmaTech Inc.
Who can join
Adults 18 to 75, female only, with Ovarian Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.
Smith BAH, Bertozzi CR. · · 2021 · cited 380× · PMID 33462432 · DOI 10.1038/s41573-020-00093-1 -
Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors.
Matsumoto Y, Ju T. · · 2023 · cited 31× · PMID 37509200 · DOI 10.3390/cancers15143536 -
Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.
Ren X, Lin S, Guan F, Kang H. · · 2024 · cited 30× · PMID 38725856 · DOI 10.7150/ijbs.93806 -
B-Cell-Based Immunotherapy: A Promising New Alternative.
Gupta SL, Khan N, Basu S, Soni V. · · 2022 · cited 29× · PMID 35746487 · DOI 10.3390/vaccines10060879 -
Immunotherapy for ovarian cancer.
Drerup JM, Liu Y, Padron AS, Murthy K, et al · · 2015 · cited 22× · PMID 25648541 · DOI 10.1007/s11864-014-0317-1 -
The role of cancer-associated mesothelial cells in the progression and therapy of ovarian cancer.
Zheng A, Wei Y, Zhao Y, Zhang T, et al · · 2022 · cited 18× · PMID 36268019 · DOI 10.3389/fimmu.2022.1013506 -
Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
Battaglia A, Buzzonetti A, Fossati M, Scambia G, et al · · 2020 · cited 18× · PMID 31897661 · DOI 10.1007/s00262-019-02456-z -
Antigen-specific active immunotherapy for ovarian cancer.
Paijens ST, Leffers N, Daemen T, Helfrich W, et al · · 2018 · cited 14× · PMID 30199097 · DOI 10.1002/14651858.cd007287.pub4
Verify or expand the search:
- PubMed search for NCT01616303
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Carboplatin
Trials testing the same drug.
- NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma · Phase 2 · withdrawn
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
Other recruiting trials for Ovarian Neoplasms
Currently open trials in the same condition.
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
- NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
- NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01616303 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Quest PharmaTech Inc.
- Last refreshed: 14 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01616303.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing